Novo Nordisk Current Ratio 2006-2018 | NVO

Historical current ratio values for Novo Nordisk (NVO) over the last 10 years.
Novo Nordisk Annual Current Ratio
2017 1.28
2016 1.26
2015 1.35
2014 1.37
2013 1.74
2012 1.86
2011 1.91
2010 2.02
2009 2.44
2008 2.24
2007 2.28
2006 2.05
2005 1.85
Novo Nordisk Quarterly Current Ratio
Q2 2018 1.17
Q1 2018 1.13
Q4 2017 1.28
Q3 2017 1.27
Q2 2017 1.35
Q1 2017 1.14
Q4 2016 1.26
Q3 2016 1.24
Q2 2016 1.27
Q1 2016 1.13
Q4 2015 1.35
Q3 2015 1.34
Q2 2015 1.23
Q1 2015 1.04
Q4 2014 1.37
Q3 2014 1.37
Q2 2014 1.44
Q1 2014 1.31
Q4 2013 1.74
Q3 2013 1.59
Q2 2013 1.44
Q1 2013 1.40
Q4 2012 1.86
Q3 2012 1.56
Q2 2012 1.51
Q1 2012 1.65
Q4 2011 1.91
Q3 2011 1.91
Q2 2011 2.04
Q1 2011 1.94
Q4 2010 2.02
Q3 2010 2.00
Q2 2010 1.85
Q1 2010 2.02
Q4 2009 2.44
Q3 2009 2.40
Q2 2009 2.38
Q1 2009 2.03
Q4 2008 2.24
Q3 2008 2.20
Q2 2008 2.38
Q1 2008 2.13
Q4 2007 2.28
Q3 2007 2.16
Q2 2007 2.17
Q1 2007 1.97
Q4 2006 2.05
Q3 2006 1.79
Q2 2006 1.99
Q1 2006 1.80
Q4 2005 1.85
Q3 2005 1.95
Q2 2005 1.87
Q1 2005 2.19
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $115.970B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
Merck (MRK) United States $186.199B 16.44
AbbVie (ABBV) United States $149.625B 14.62
Eli Lilly (LLY) United States $113.359B 20.98
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62